TKIs, Disease Progression and Subsequent Therapy in RCC

Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma.

EP: 1.Overview of RCC Histology and Incidence Rates

EP: 2.CLEAR Trial Updates From ASCO 2024

Now Viewing

EP: 3.TKIs, Disease Progression and Subsequent Therapy in RCC

EP: 4.ASCO 2024 Updates: nccRCC + Chromophobe RCC

EP: 5.PAPMET Phase II Trial Advances Cancer Treatment Landscape

EP: 6.Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis

EP: 7.Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence

EP: 8.ASCO 2024: Abstract 4512 Overview

EP: 9.Key Takeaways in Renal Cell Carcinoma from Abstract 4512

EP: 10.Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials

Recent Videos